Know Cancer

or
forgot password

Fluoropyrimidine/Platinum-based First-line Chemotherapy in Metastatic Esophageal Squamous Cell Carcinoma: Prognostic Factor Analysis in 239 Patients


N/A
18 Years
N/A
Not Enrolling
Both
Metastatic Esophageal Squamous Cell Carcinoma

Thank you

Trial Information

Fluoropyrimidine/Platinum-based First-line Chemotherapy in Metastatic Esophageal Squamous Cell Carcinoma: Prognostic Factor Analysis in 239 Patients


Inclusion Criteria:



- recurrent, metastatic esophageal SCC

- received either FP or XP as first-line chemotherapy.

Exclusion Criteria:

Type of Study:

Observational

Study Design:

Time Perspective: Retrospective

Outcome Measure:

Overall Survival

Outcome Time Frame:

12 month

Safety Issue:

Yes

Principal Investigator

Jeeyun Lee, M.D., Ph.D.

Investigator Role:

Principal Investigator

Investigator Affiliation:

Samsung Medical Center, Seoul, Korea

Authority:

South Korea: Institutional Review Board

Study ID:

SMCESOPROGNOSIS

NCT ID:

NCT01472419

Start Date:

March 2012

Completion Date:

March 2013

Related Keywords:

  • Metastatic Esophageal Squamous Cell Carcinoma
  • metastatic esophageal squamous cell carcinoma
  • Fluoropyrimidine/platinum-based first-line chemotherapy
  • prognosis
  • Carcinoma
  • Carcinoma, Squamous Cell
  • Esophageal Diseases

Name

Location